Regeneron price target raised to $1,282 from $1,250 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Regeneron to $1,282 from $1,250 and keeps an Outperform rating on the shares. The company’s other pipeline agents have garnered more attention of late, but its Factor XI antibodies program is advancing rapidly, and the firm’s closer look suggests that the promising target, differentiated features of its antibodies, and its large market opportunity should command greater attention, which it anticipates to materialize as phase 2 TKA proof of concept data approaches, the analyst tells investors in a research note.